Expression of IL-33 in serum and skin lesions of 126 patients with progressive psoriasis vulgaris

Abstract

Objective: To investigate the expression of IL-33 in serum and skin lesions of patients with progressive psoriasis vulgaris (PsV) and its clinical significance. Methods: A total of 126 patients with PsV and 45 healthy individuals were enrolled from January 2018 to January 2019 which defined as PsV group and control group, respectively. The differences of IL-33 expression in serum between the two groups were analyzed and compared, and the differences of IL-33 expression in skin tissue between patients with PsV and lipoma patients were also compared. The serum IL-33 expression levels with PASI scores correlation, differences between clinical characteristics and influencing factors in patients with PsV were analyzed by Pearson correlation analysis, single factor analysis and logistic regression analysis, respectively. Receiver Operating Characteristic (ROC) curve was used to investigate the clinical efficacy of serum IL-33 levels in differentiating PsV from control group, mild from moderate to severe PsV. Results: Compared with the control group, the expression of IL-33 in the serum of the patients with PsV was significantly higher (t=17.51, P<0.01), and the expression of IL-33 in the skin lesions of the patients with moderate to severe PsV (16.56±4.18) was significantly higher than that of the patients with mild PsV (9.28±1.04) and the lipoma patients (5.64±1.45) (t=7.56、11.04, respectively, both P<0.05). The expression of IL-33 in the skin lesions of the patients with mild PsV were significantly higher than that of the lipoma patients (t=9.12, P<0.05). Pearson correlation analysis showed that serum IL-33 was positively correlated with PASI scores (r=0.85, P<0.01). The serum IL-33 expression levels was different significantly between different BMI, course of disease and severity of skin lesions of patients with PsV. Duration (OR=3.449), PASI (OR=10.444) were positively correlated to serum IL-33 levels in patients with PsV. ROC curve showed that serum IL-33 levels in differentiating progressive PsV from control group, mild from moderate to severe progressive PsV were significantly. The AUC was 0.945 and 0.870, respectively. Conclusions: The expression of IL-33 in serum and lesions of patients with PsV were significantly increased, and IL-33 may be involved in the pathogenesis of psoriasis.

Keywords

• psoriasis vulgaris
• il-33
• inflammatory factors
• influencing factors
• roc curve